Loading...
Loading...
ShangPharma Corporation
SHP (the "Company"), a leading China-based pharmaceutical and biotechnology
research and development outsourcing company, today announced that the Company
has entered into a definitive Agreement and Plan of Merger (the "Merger
Agreement") with ShangPharma Holdings Limited ("Holdings"), ShangPharma Parent
Limited ("Parent") and ShangPharma Merger Sub Limited ("Merger Sub"), pursuant
to which Parent will acquire the Company for US$0.50 per ordinary share or
US$9.00 per American Depositary Share, each representing eighteen ordinary
shares ("ADS"). This represents a 30.8% premium over the closing price of
$6.88 per ADS as quoted by the New York Stock Exchange (the "NYSE") on July 5,
2012, the last trading day prior to the Company's announcement on July 6, 2012
that it had received a "going private" proposal, and a 44.8% and 34.2% premium
to the volume-weighted average closing price of the Company's ADSs during the
30 and 60 trading days prior to August 13, 2012, respectively. The
consideration to be paid to holders of ordinary shares and ADSs implies an
equity value of the Company at approximately US$173 million, on a fully
diluted basis.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in